North America Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and Targeted Therapy), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2022 - 2028

The North America Head And Neck Cancer Therapeutics Market should witness market growth of 11.2% CAGR during the forecast period (2022-2028).

A record of tobacco consumption or contact with the human papillomavirus is frequently linked to squamous cell carcinoma (HPV). In addition to salivary gland tumors, lymphomas, and sarcomas, there are a few less frequent kinds of head and neck cancer. In addition to preventing the consumption of alcohol and cigarette products, children and young people can be vaccinated against HPV.

There are four primary modes of cancer's spread, the first is the direct expansion of the core location to neighboring places. The second is transmitted to lymph nodes through lymphatic pathways. The third kind spreads via nerves to various parts of the head and neck (perineural spread). The fourth is distributed throughout the body via the blood vessels.

It is typical for head and neck cancer to move to the lymph nodes in the neck. The lymph nodes that are most frequently affected depend on the origin of the main tumor. The majority of lymph nodes are situated along major blood veins under the sternocleidomastoid muscle on both sides of the neck.

In the United States, roughly 4% of all malignancies are head and neck cancers. These malignancies are more than double as prevalent in males as in women. Head and neck cancers are also detected more frequently in those over 50 than in those under 50. It isanticipated that even more than 68,000 men and women will be diagnosed with head and neck malignancies in the United States in 2021. The majority will be diagnosed with cancer of the mouth, throat, or voice box.

The US market dominated the North America Head & Neck Cancer Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $743.3 Million by 2028. The Canada market is poised to grow at a CAGR of 13.3% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 13% during (2022-2028).

Based on Therapy Type, the market is segmented into Immunotherapy, Chemotherapy, and Targeted Therapy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.

Scope of the Study

By Therapy Type

• Immunotherapy
• Chemotherapy
• Targeted Therapy

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Retail & Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Eli Lilly and Company
• Merck & Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceuticals Industries Ltd.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca Plc
• Bristol Myers Squibb Company
• Clinigen Group PLC

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free